Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone

Bioconjugate Chemistry

Volumn 22, Issue 12, 2011, Pages 2496-2506

  Yewle, Jivan N ^a   Puleo, David A ^b   Bachas, Leonidas G ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c Department of Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; CONTROLLED DRUG DELIVERY; DISEASES; DRUG INTERACTIONS; HYDROXYAPATITE; NITROGEN COMPOUNDS; TARGETED DRUG DELIVERY;

BI-FUNCTIONAL; BISPHOSPHONATES; BONE DISEASE; HIGH AFFINITY; NON-TARGETED; SKELETAL DISEASE; TARGETED DELIVERY; THERAPEUTIC AGENTS; THERAPEUTIC TREATMENTS; WOUND HEALING;

BONE;

4 NITROBENZALDEHYDE; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; HYDRAZINE; HYDROXYAPATITE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BONE; CELL PROLIFERATION; CONTROLLED STUDY; CRYSTALLIZATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HUMAN CELL; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; WOUND HEALING;

EID: 84555186709     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc2003132     Document Type: Article

References (56)

1. Langer, R. (2001) Drug delivery: Drugs on target Science 293, 58-59
2. Harada, S. and Rodan, G. A. (2003) Control of osteoblast function and regulation of bone mass Nature 423, 349-355 (Pubitemid 40852710)
3. Goltzman, D. (2002) Discoveries, drugs and skeletal disorders Nat. Rev. Drug Discovery 1, 784-796 (Pubitemid 37361562)
4. Salo, J., Lehenkari, P., Mulari, M., Metsikkö, K., and Väänänen, H. K. (1997) Removal of osteoclast bone resorption products by transcytosis Science 276, 270-273 (Pubitemid 27172688)
5. Deal, C. (2009) Future therapeutic targets in osteoporosis Curr. Opin. Rheumatol. 21, 380-385
6. Vondracek, S. F. and Linnebur, S. A. (2009) Diagnosis and management of osteoporosis in the older senior Clin. Interventions Aging 4, 121-136
7. Rodan, G. A. and Martin, T. J. (2000) Therapeutic approaches to bone diseases Science 289, 1508-1514
8. Polascik, T. J. (2009) Bisphosphonates in oncology: Evidence for the prevention of skeletal events in patients with bone metastases Drug Des., Dev. Ther. 3, 27-40
9. Lumachi, F., Brunello, A., Roma, A., and Basso, U. (2008) Medical treatment of malignancy-associated hypercalcemia Curr. Med. Chem. 15, 415-421 (Pubitemid 351266947)
10. Zhang, S., Gangal, G., and Uludaǧ, H. (2007) Magic bullets for bone diseases: Progress in rational design of bone-seeking medicinal agents Chem. Soc. Rev. 36, 507-531
11. van Beek, E. R., Lowik, C., Que, I., and Papapoulos, S. (1996) Dissociation of binding and antiresorptive properties of hydroxy bisphosphonates by substitition of the hydroxyl with an amino group J. Bone Miner. Res. 11, 1492-1497 (Pubitemid 26331004)
12. Sunberg, R. J., Ebetino, F. H., Mosher, C. T., and Roof, C. F. (1991) Designing drugs for stronger bones CHEMTECH 21, 305-309
13. Chapurlat, R. D. and Delmas, P. D. (2006) Drug insight: Bisphosphonates for postmenopausal osteoporosis Nat. Clin. Pract. Endocrinol. Metab. 2, 211-219
14. Peppas, N. A. (2004) Intelligent therapeutics: Biomimetic systems and nanotechnology in drug delivery Adv. Drug Delivery Rev. 56, 1529-1531 (Pubitemid 39177686)
15. Peppas, N. A. (2006) Vecteurs de médicaments innovants et ? intelligents ?: leurs applications pharmaceutiques Ann. Pharm. Fr. 64, 260-275
16. Langer, R. and Peppas, N. A. (2003) Advances in biomaterials, drug delivery, and bionanotechnology AIChE J. 49, 2990-3006 (Pubitemid 38009884)
17. Oh, Y.-K., Senter, P. D., and Song, S.-C. (2009) Intelligent drug delivery systems Bioconjugate Chem. 20, 1813-1815
18. MacEwan, S. R. and Chilkoti, A. (2010) Elastin-like polypeptides: Biomedical applications of tunable biopolymers Pept. Sci. 94, 60-77
19. Betre, H., Liu, W., Zalutsky, M. R., Chilkoti, A., Kraus, V. B., and Setton, L. A. (2006) A thermally responsive biopolymer for intra-articular drug delivery J. Controlled Release 115, 175-182 (Pubitemid 44537500)
20. Wang, D., Miller, S. C., Shlyakhtenko, L. S., Portillo, A. M., Liu, X.-M., Papangkorn, K., Kopečková, P., Lyubchenko, Y., Higuchi, W. I., and Kope?ek, J. (2007) Osteotropic peptide that differentiates functional domains of the skeleton Bioconjugate Chem. 18, 1375-1378 (Pubitemid 47464042)
21. Wang, D., Sima, M., Mosley, R. L., Davda, J. P., Tietze, N., Miller, S. C., Gwilt, P. R., Kopečková, P., and Kope?ek, J. (2006) Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-Hydroxypropyl)methacrylamide copolymers Mol. Pharmaceutics 3, 717-725 (Pubitemid 46087487)
22. Thompson, W. J., Thompson, D. D., Anderson, P. S., and Rodan, G. A. (1989) Polymalonic acids as boneaffinity agents, EP 0341961.
23. Orme, M. W. and Labroo, V. M. (1994) Synthesis of [beta]-estradiol-3- benzoate-17-(succinyl-12A-tetracycline): A potential bone-seeking estrogen Bioorg. Med. Chem. Lett. 4, 1375-1380 (Pubitemid 24205618)
24. Zheng, H. and Weng, L. (1997) Bone resorption inhibition/osteogenesis promotion pharmaceutical composition, U.S. Patent 5,698,542.
25. Hirabayashi, H., Takahashi, T., Fujisaki, J., Masunaga, T., Sato, S., Hiroi, J., Tokunaga, Y., Kimura, S., and Hata, T. (2001) Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the osteotropic drug delivery system (ODDS) J. Controlled Release 70, 183-191 (Pubitemid 32144802)
26. Gil, L., Han, Y., Opas, E. E., Rodan, G. A., Ruel, R., Seedor, J. G., Tyler, P. C., and Young, R. N. (1999) Prostaglandin E2-bisphosphonate conjugates: Potential agents for treatment of osteoporosis Bioorg. Med. Chem. 7, 901-919 (Pubitemid 29238086)
27. Ora, M., Lönnberg, T., Florea-Wang, D., Zinnen, S., Karpeisky, A., and Lönnberg, H. (2008) Bisphosphonate derivatives of nucleoside antimetabolites: Hydrolytic stability and hydroxyapatite adsorption of 5?-β,γ-methylene and 5?-β,γ-(1-hydroxyethylidene) triphosphates of 5-fluorouridine and ara-cytidine J. Org. Chem. 73, 4123-4130 (Pubitemid 351812913)
28. El-Mabhouh, A., Angelov, C., McEwan, A., Jia, G., and Mercer, J. (2004) Preclinical investigations of drug and radionuclide conjugates of bisphosphonates for the treatment of metastatic bone cancer Cancer Biother. Radiopharm. 19, 627-640 (Pubitemid 39546303)
29. Herczegh, P., Buxton, T. B., McPherson, J. C. I., Kovács-Kulyassa, Á., Brewer, P. D., Sztaricskai, F., Stroebel, G. G., Plowman, K. M., Farcasiu, D., and Hartmann, J. F. (2002) Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials J. Med. Chem. 45, 2338-2341 (Pubitemid 34525812)
30. Wang, J. B., Yang, C. H., Yan, X. M., Wu, X. H., and Xie, Y. Y. (2005) Novel bone-targeted agents for treatment of osteoporosis Chin. Chem. Lett. 16, 859-862 (Pubitemid 43872249)
31. Blower, P. (2006) Towards molecular imaging and treatment of disease with radionuclides: The role of inorganic chemistry Dalton Trans. 1705-1711
32. 99mTc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent J. Nucl. Med. 47, 2042-2047 (Pubitemid 47544992)
33. 3-dipicolylamine- alendronate: A new bisphosphonate conjugate for the radiotherapy of bone metastases Bioconjugate Chem. 21, 811-815
34. Zaheer, A., Lenkinski, R. E., Mahmood, A., Jones, A. G., Cantley, L. C., and Frangioni, J. V. (2001) In vivo near-infrared fluorescence imaging of osteoblastic activity Nat. Biotechnol. 19, 1148-1154 (Pubitemid 33115701)
35. 131I]-labeled arylalkylidenebisphosphonates: Potent bone-seekers for diagnosis and therapy of malignant osseous lesions J. Med. Chem. 46, 3021-3032 (Pubitemid 36780939)
36. Ehrick, R. S., Capaccio, M., Puleo, D. A., and Bachas, L. G. (2007) Ligand-modified aminobisphosphonate for linking proteins to hydroxyapatite and bone surface Bioconjugate Chem. 19, 315-321
37. Uludaǧ, H. (2002) Bisphosphonates as a foundation of drug delivery to bone Curr. Pharm. Des. 8, 1929-1944
38. Doschak, M. R., Kucharski, C. M., Wright, J. E. I., Zernicke, R. F., and Uludaǧ, H. (2009) Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis Mol. Pharmaceutics 6, 634-640
39. Kieczykowski, G. R., Jobson, R. B., Melillo, D. G., Reinhold, D. F., Grenda, V. J., and Shinkai, I. (1995) Preparation of (4-amino-1- hydroxybutylidene)bisphosphonic acid sodium salt, MK-217 (alendronate sodium). An improved procedure for the preparation of 1-hydroxy-1,1-bisphosphonic acids J. Org. Chem. 60, 8310-8312 (Pubitemid 26236986)
40. Chebbi, I., Migianu-Griffoni, E., Sainte-Catherine, O., Lecouvey, M., and Seksek, O. (2010) In vitro assessment of liposomal neridronate on MDA-MB-231 human breast cancer cells Int. J. Pharm. 383, 116-122
41. Rodan, G. A. and Fleisch, H. A. (1996) Bisphosphonates: Mechanisms of action J. Clin. Invest. 97, 2692-2696 (Pubitemid 26197084)
42. Koutsoukos, P., Amjad, Z., Tomson, M. B., and Nancollas, G. H. (1980) Crystallization of calcium phosphates. A constant composition study J. Am. Chem. Soc. 102, 1553-1557
43. Nancollas, G. H., Tang, R., Phipps, R. J., Henneman, Z., Gulde, S., Wu, W., Mangood, A., Russell, R. G. G., and Ebetino, F. H. (2006) Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite Bone 38, 617-627
44. Fleisch, H. (1998) Bisphosphonates: mechanisms of action Endocr. Rev. 19, 80-100 (Pubitemid 29122075)
45. Rodan, G. A. (1998) Mechanisms of action of bisphosphonates Annu. Rev. Pharmacol. Toxicol. 38, 375-388 (Pubitemid 28231500)
46. Roelofs, A. J., Thompson, K., Gordon, S., and Rogers, M. J. (2006) Molecular mechanisms of action of bisphosphonates: Current status Clin. Cancer Res. 12, 6222s-6230s (Pubitemid 44703794)
47. Segal, E., Pan, H., Ofek, P., Udagawa, T., Kopečková, P., Kopeek, J., and Satchi-Fainaro, R. (2009) Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics PloS ONE 4, e5233
48. Segal, E., Pan, H., Benayoun, L., Kopečková, P., Shaked, Y., Kopeek, J., and Satchi-Fainaro, R. (2011) Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances Biomaterials 32, 4450-4463
49. Schneider, L., Korber, A., Grabbe, S., and Dissemond, J. (2007) Influence of pH on wound-healing: A new perspective for wound-therapy? Arch. Dermatol. Res. 298, 413-420 (Pubitemid 46144202)
50. Teitelbaum, S. L. (2000) Bone resorption by osteoclasts Science 289, 1504-1508
51. Xu, S., Krämer, M., and Haag, R. (2006) pH-Responsive dendritic core-shell architectures as amphiphilic nanocarriers for polar drugs J. Drug Targeting 14, 367-374 (Pubitemid 44203517)
52. Kale, A. A. and Torchilin, V. P. (2007) Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: The effect of substitutes at the hydrazone linkage on the pH stability of PEG-PE conjugates Bioconjugate Chem. 18, 363-370 (Pubitemid 46493506)
53. Sawant, R. M., Hurley, J. P., Salmaso, S., Kale, A., Tolcheva, E., Levchenko, T. S., and Torchilin, V. P. (2006) SMART" drug delivery systems: Double-targeted pH-responsive pharmaceutical nanocarriers Bioconjugate Chem. 17, 943-949 (Pubitemid 44162612)
54. Prommer, E. E. (2009) Toxicity of bisphosphonates J. Palliat. Med. 12, 1661-1665
55. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. (1994) Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE Nature 371, 346-347 (Pubitemid 24300618)
56. Pan, H., Kopečková, P., Wang, D., Yang, J., Miller, S., and Kope?ek, J. (2006) Water-soluble HPMA copolymer - prostaglandin E1 conjugates containing a cathepsin K sensitive spacer J. Drug Targeting 14, 425-435 (Pubitemid 44203521)